Guanfacine hydrochloride extended release (Intuniv XR) tablets for the treatment of attention-deficit/hyperactivity disorder
The objective of this review was to compare the clinical benefits and harms of guanfacine extended release (GXR; brand name: Intuniv XR) with those of other active treatments and placebo in children aged six to 12 years with attention-deficit/hyperactivity disorder (ADHD)
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2015, 2015
|
| Series: | Common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review was to compare the clinical benefits and harms of guanfacine extended release (GXR; brand name: Intuniv XR) with those of other active treatments and placebo in children aged six to 12 years with attention-deficit/hyperactivity disorder (ADHD) |
|---|---|
| Physical Description: | 1 online resource |